Non-Small-Cell Lung Cancer
Non-Small-Cell Lung Cancer (NSCLC) is the most common type of lung cancer, which develops in the lungs and can cause symptoms like persistent cough, chest pain, and difficulty breathing.
Lung Cancer: Pembrolizumab and Lenvatinib Combination Therapy
We are studying a new combination treatment for patients with operable Non-Small-Cell Lung Cancer to see if it improves response rates before surgery. We also aim to identify markers that may predict how well patients respond to this therapy.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have a confirmed diagnosis of non-small cell lung cancer (NSCLC) that can be surgically removed?
- Are you currently pregnant or breastfeeding?
- Have you had any major surgery for your lung cancer in the past 3 months?
- Are you taking any medications that suppress your immune system, like steroids or other immunosuppressive drugs?
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Kisplyx
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Medizinische Universitaet Innsbruck
Internal Medicine V
Innsbruck, Austria
Sponsor: Medizinische Universitaet Innsbruck
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.